Bristol Myers Squibb selected Houston for a new $2.3 billion multi-modal manufacturing campus designed to support drug product and finished goods from late development through launch. The site will be built within Generation Park and aims to cover multiple modality types, including small molecules, biologics, and antibody-drug conjugates. The project is part of BMS’s broader U.S. investment commitment of $40 billion over five years spanning R&D, technology, and manufacturing. BMS board chair and CEO Christopher Boerner said the move is aimed at building domestic manufacturing capabilities to support next-generation medicines. The Houston plan adds to existing U.S. reshoring momentum in large biopharma, including Eli Lilly’s parallel manufacturing expansion at Generation Park and its related local dealmaking. For biotech and supply-chain partners, the campus signals continued demand for upstream and fill-finish capabilities in the U.S. market.